A Study to Investigate the Safety and Effectiveness of RO7759065 in Combination with Atezolizumab in Participants with Locally Advanced or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Registration Number
- 2024-513391-17-00
- Lead Sponsor
- Genentech Inc., Genentech Inc., Genentech Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruiting
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (14)
Institut Curie
🇫🇷Paris, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Institut Bergonie
🇫🇷Bordeaux, France
Centre Leon Berard
🇫🇷Lyon, France
Fondazione IRCCS Istituto Nazionale Dei Tumori
🇮🇹Milan, Italy
Humanitas Mirasole S.p.A.
🇮🇹Rozzano, Italy
Ospedale San Raffaele S.r.l.
🇮🇹Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
🇮🇹Rome, Italy
Hospital Universitario 12 De Octubre
🇪🇸Madrid, Spain
Clinica Universidad De Navarra
🇪🇸Pamplona, Spain
Scroll for more (4 remaining)Institut Curie🇫🇷Paris, FranceChristophe LE TOURNEAUSite contact+33144324017christophe.letourneau@curie.fr